Core Viewpoint - Marex Group plc is facing a class action securities lawsuit due to alleged securities fraud that occurred between May 16, 2024, and August 5, 2025, which has adversely affected investors [1][2] Group 1: Lawsuit Details - The lawsuit claims that Marex Group plc made false statements and concealed information regarding the improper inflation of cash flow, revenues, assets, and profits in its Market Making segment through off-book intercompany transactions [2] - As a result of these actions, the positive statements made by the defendants about the Company's business and prospects were materially false and misleading [2] Group 2: Next Steps for Investors - Investors who suffered losses during the specified timeframe have until December 8, 2025, to request to be appointed as lead plaintiff, although participation in any recovery does not require serving as a lead plaintiff [3] - Class members may be entitled to compensation without any out-of-pocket costs or fees [3] Group 3: Firm Background - Levi & Korsinsky, LLP has a strong track record, having secured hundreds of millions of dollars for shareholders over the past 20 years and is recognized as one of the top securities litigation firms in the United States [4]

Group 1 - The Value Lab focuses on long-only value investment ideas, aiming for a portfolio yield of approximately 4% and has performed well over the last five years by engaging in international markets [1][2] - The Valkyrie Trading Society consists of analysts who share high conviction and obscure developed market ideas, targeting downside-limited investments that are expected to yield non-correlated and outsized returns in the current economic environment [2] - The Value Lab provides members with real-time portfolio updates, 24/7 chat support, regular global market news reports, feedback on stock ideas, monthly new trades, quarterly earnings write-ups, and daily macro opinions [2]

Core Viewpoint - Class action lawsuits have been filed against several publicly-traded companies, alleging that these companies made materially false and misleading statements regarding their business operations and financial prospects, which have adversely affected shareholders [1]. Company Summaries Molina Healthcare, Inc. (NYSE: MOH) - Class Period: February 5, 2025 – July 23, 2025 - Allegations include failure to disclose adverse facts about medical cost trend assumptions and a dislocation between premium rates and medical costs, leading to a likely cut in financial guidance for fiscal year 2025 [2]. Marex Group plc (NASDAQ: MRX) - Class Period: May 16, 2024 – August 5, 2025 - Allegations include selling over-the-counter financial instruments to itself and inconsistencies in financial statements, making the financial data unreliable [3]. aTyr Pharma Inc. (NASDAQ: ATYR) - Class Period: November 7, 2024 – September 12, 2025 - Allegations include misleading statements regarding the study design for EFZO-FIT and the failure to meet primary endpoints, which misrepresented the company's prospects [4]. WPP plc (NYSE: WPP) - Class Period: February 27, 2025 – July 8, 2025 - Allegations include the media arm's inability to handle macroeconomic challenges and loss of market share, rendering positive statements about the company's operations misleading [6].

Core Viewpoint - Marex Group plc is facing a class action securities lawsuit due to alleged securities fraud that inflated its financial metrics, impacting investors negatively between May 16, 2024, and August 5, 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit claims that Marex Group plc made false statements and concealed information regarding the improper inflation of cash flow, revenues, assets, and profits in its Market Making segment through off-book intercompany transactions [2]. - As a result of these actions, the positive statements made by the defendants about the Company's business and prospects were materially false and misleading [2]. Group 2: Investor Information - Investors who suffered losses during the specified timeframe have until December 8, 2025, to request to be appointed as lead plaintiff, although participation in any recovery does not require serving as a lead plaintiff [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees, indicating no financial obligation to participate in the lawsuit [3]. Group 3: Legal Firm Background - Levi & Korsinsky, LLP has a strong track record, having secured hundreds of millions of dollars for shareholders over the past 20 years and is recognized as one of the top securities litigation firms in the United States [4].

Core Viewpoint - The Rosen Law Firm is encouraging investors of Marex Group plc to secure legal counsel before the December 8, 2025 deadline for a securities class action lawsuit related to misleading financial statements and practices during the Class Period from May 16, 2024, to August 5, 2025 [2][6]. Group 1: Legal Action Details - Investors who purchased Marex securities during the Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [3]. - The lawsuit alleges that Marex made materially false and misleading statements, including selling over-the-counter financial instruments to itself and inconsistencies in financial statements between subsidiaries [6]. - The lawsuit claims that these misleading statements resulted in investor damages when the true details became public [6]. Group 2: Next Steps for Investors - To join the class action, investors can visit the provided link or contact the law firm directly for more information [4][7]. - A lead plaintiff must be appointed by December 8, 2025, to represent other class members in the litigation [4]. - Investors have the option to select their counsel or remain absent from the class at this stage [8]. Group 3: Rosen Law Firm's Credentials - The Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements and recognition in the field [5]. - The firm was ranked No. 1 for securities class action settlements in 2017 and has recovered hundreds of millions for investors over the years [5].

Core Points - Class action lawsuits have been filed on behalf of shareholders of several publicly-traded companies, with specific deadlines for filing lead plaintiff motions [1] Company Summaries Molina Healthcare, Inc. (NYSE: MOH) - Class Period: February 5, 2025 – July 23, 2025 - Allegations include false and misleading statements regarding medical cost trend assumptions, dislocation between premium rates and medical costs, and reliance on reduced utilization of services, leading to likely cuts in financial guidance for fiscal year 2025 [2] Marex Group plc (NASDAQ: MRX) - Class Period: May 16, 2024 – August 5, 2025 - Allegations include selling over-the-counter financial instruments to itself, inconsistencies in financial statements, and reliance issues with financial statements, resulting in misleading positive statements about the company's operations and prospects [3] WPP plc (NYSE: WPP) - Class Period: February 27, 2025 – July 8, 2025 - Allegations include the media arm's inability to handle macroeconomic challenges and loss of market share, leading to misleading positive statements about the company's business and operations [4]

Core Viewpoint - A class action lawsuit has been filed against Marex Group plc due to allegations of financial improprieties, including a multi-year accounting scheme that concealed losses and inflated profits [1][3][4]. Group 1: Lawsuit Details - The lawsuit is on behalf of investors who purchased Marex shares from May 16, 2024, to August 5, 2025 [1][2]. - Investors have until December 8, 2025, to seek appointment as lead plaintiff [2]. Group 2: Allegations Against Marex - NINGI Research reported that Marex engaged in a multi-year accounting scheme involving off-balance-sheet entities and fictitious transactions [3]. - The report highlighted discrepancies in intercompany receivables and loans across over 56 entities, amounting to multi-million-dollar differences [3]. - Marex allegedly concealed nearly $1 billion in off-balance-sheet derivatives, inflating operating cash flow by misclassifying structured note issuance as income [4]. Group 3: Market Reaction - Following the release of the report, Marex's stock price fell by $2.33, or 6.2%, closing at $35.31, resulting in significant investor losses [4].

Core Viewpoint - Rosen Law Firm is encouraging investors of Marex Group plc who incurred losses exceeding $100,000 during the specified class period to seek legal counsel before the December 8, 2025 deadline for lead plaintiff applications [1]. Group 1: Legal Action Details - Investors who purchased Marex securities between May 16, 2024, and August 5, 2025, may be eligible for compensation without upfront costs through a contingency fee arrangement [2]. - To participate in the class action, investors can visit the provided link or contact the law firm directly for more information [3][6]. - The lawsuit alleges that Marex made materially false statements and failed to disclose critical information regarding its financial practices, leading to investor damages when the truth was revealed [5]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest against a Chinese company [4]. - The firm has been recognized for its success in securities class action settlements, ranking No. 1 in 2017 and consistently in the top 4 since 2013, recovering hundreds of millions for investors [4]. - In 2019, the firm secured over $438 million for investors, showcasing its capability in handling such cases [4].

Core Points - Rosen Law Firm is reminding investors who purchased securities of Marex Group plc between May 16, 2024, and August 5, 2025, about the December 8, 2025, lead plaintiff deadline for a class action lawsuit [1] - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1] Case Details - The lawsuit alleges that during the Class Period, Marex made materially false and misleading statements and failed to disclose critical information, including: 1. Marex sold over-the-counter financial instruments to itself 2. There were inconsistencies in financial statements between subsidiaries and related parties 3. Marex's financial statements could not be relied upon 4. Positive statements about Marex's business were materially misleading [4] Legal Representation - Investors are encouraged to select qualified counsel with a successful track record in securities class actions, as many firms may not have the necessary experience or resources [3] - Rosen Law Firm has achieved significant settlements for investors, including over $438 million in 2019 and has been ranked highly for its performance in securities class action settlements [3]

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Marex Group plc due to allegations of securities law violations, with a deadline for investors to seek lead plaintiff status in a class action lawsuit by December 8, 2025 [3][6]. Group 1: Allegations Against Marex - The complaint alleges that Marex and its executives made false and misleading statements and failed to disclose critical information, including the sale of over-the-counter financial instruments to itself and inconsistencies in financial statements [6]. - A report from NINGI Research accused Marex of a multi-year accounting scheme involving off-balance-sheet entities and fictitious transactions, including a fabricated receivable of $17 million and nearly $1 billion in concealed derivatives exposure [7]. - Following the release of the report, Marex's stock experienced a significant decline of 6.2%, closing at $35.31 on heavy trading volume [9]. Group 2: Legal Actions and Investor Options - Investors who purchased Marex securities between May 16, 2024, and August 5, 2025, are encouraged to contact Faruqi & Faruqi to discuss their legal rights and options [2]. - The firm has a history of recovering hundreds of millions of dollars for investors since its founding in 1995, indicating its capability in handling such cases [5]. - Any member of the putative class can move the court to serve as lead plaintiff or choose to remain an absent class member, with no impact on their ability to share in any recovery [10].